IDO1 and central nervous system cancer: Since IDO [indoleamine (2,3)-dioxygenase] expressed by glioma cells is essential for recruitment of Tregs, the use of IDO inhibitors has been shown to decrease the overall accumulation of Tregs and enhance survival in established glioma (189).